Search research articles
Contact Us
Filters
Showing results (71-80 of 108) with videos related to
Page
of 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 16, 2021
The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma
Shwetha H Manjunath, Adam D Cohen, Simon F Lacey, et al.
Blood
|
June 27, 2023
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
Morie A Gertz, Adam D Cohen, Raymond L Comenzo, et al.
The New England Journal of Medicine
|
September 10, 2015
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L Garfall, Marcela V Maus, Wei-Ting Hwang, et al.
Journal for Immunotherapy of Cancer
|
July 15, 2020
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
Nina Shah, Jack Aiello, David E Avigan, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 5, 2006
DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation
Miguel-Angel Perales, Adi Diab, Adam D Cohen, et al.
Plos One
|
December 19, 2013
Enhanced responses to tumor immunization following total body irradiation are time-dependent
Adi Diab, Robert R Jenq, Gabrielle A Rizzuto, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 10, 2022
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study
Adam D Cohen, Parameswaran Hari, Myo Htut, et al.
The Lancet. Oncology
|
September 1, 2020
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Shaji K Kumar, Susanna J Jacobus, Adam D Cohen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
November 3, 2009
NCCN clinical practice guidelines in oncology: multiple myeloma
Kenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Cancer
|
August 25, 2023
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial
Ajay K Nooka, Adam D Cohen, Hans C Lee, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 108) with videos related to
Sort By:
Page
of 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 16, 2021
The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma
Shwetha H Manjunath, Adam D Cohen, Simon F Lacey, et al.
Blood
|
June 27, 2023
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
Morie A Gertz, Adam D Cohen, Raymond L Comenzo, et al.
The New England Journal of Medicine
|
September 10, 2015
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L Garfall, Marcela V Maus, Wei-Ting Hwang, et al.
Journal for Immunotherapy of Cancer
|
July 15, 2020
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
Nina Shah, Jack Aiello, David E Avigan, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 5, 2006
DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation
Miguel-Angel Perales, Adi Diab, Adam D Cohen, et al.
Plos One
|
December 19, 2013
Enhanced responses to tumor immunization following total body irradiation are time-dependent
Adi Diab, Robert R Jenq, Gabrielle A Rizzuto, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 10, 2022
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study
Adam D Cohen, Parameswaran Hari, Myo Htut, et al.
The Lancet. Oncology
|
September 1, 2020
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Shaji K Kumar, Susanna J Jacobus, Adam D Cohen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
November 3, 2009
NCCN clinical practice guidelines in oncology: multiple myeloma
Kenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Cancer
|
August 25, 2023
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial
Ajay K Nooka, Adam D Cohen, Hans C Lee, et al.
Page
of 11